Emergent BioSolutions Inc. (NYSE:EBS) announced today that Don Elsey,
its chief financial officer (CFO) and senior vice president of finance
and administration, has been named 2009 SmartCFO of the Year by SmartCEO
Magazine. This annual award is based on votes from SmartCFO finalists
selected from the Washington-Baltimore region in April for exhibiting
exemplary skills in maintaining a company’s financial integrity.
“I am deeply honored to have received this recognition from my peers,”
said Elsey. When asked what has been his proudest moment as CFO of
Emergent, Elsey responded, “I am most proud of building an incredibly
talented finance, IT, and HR team who not only supports the entire
organization for growth, but also plays a vital role in making that
growth possible.”
Elsey’s over 20 years of cumulative experience in the finance and life
sciences industries have effectively contributed to the company’s
expansion, with Emergent posting seven consecutive years of growth and
profitability. In 2006, Elsey was also instrumental in transitioning
Emergent from a private to a public company.
SmartCEO Magazine recognizes that “the role of a successful chief
financial officer goes far beyond finance and numbers. While finance is
the main area a CFO oversees, the CFOs profiled…are effective managers,
visionaries and trusted advisors to the CEO and executive management
team.”
“Don is definitely deserving of this award,” stated Fuad El Hibri,
chairman and chief executive officer of Emergent BioSolutions. “Our
shared vision for growth supported by his steady stewardship of
Emergent’s resources has contributed greatly to our company being
recognized by Wall Street as one of the top performing biopharmaceutical
companies.”
The selection criteria for a SmartCFO include having an overall positive
impact on the company’s bottom line, a unique style of cash flow
management, a strong adherence to ethics and morals, and success in
mergers and acquisitions, among others.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the
development, manufacture and commercialization of vaccines and
therapeutics that assist the body’s immune system to prevent or treat
disease. Emergent’s marketed product, BioThrax® (Anthrax
Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and
Drug Administration for the prevention of anthrax. Emergent’s
development pipeline includes programs focused on anthrax, botulism,
tuberculosis, typhoid, hepatitis B and chlamydia. Additional information
may be found at www.emergentbiosolutions.com.
Emergent BioSolutions Inc.
Investors Contact:
Robert
G. Burrows
Vice President, Investor Relations
301-795-1877
BurrowsR@ebsi.com
or
Media
Contact:
Tracey Schmitt
Vice President, Corporate
Communications
301-795-1800
SchmittT@ebsi.com
